Feixiang Wang, Rujuan Bao, Shuiyu Xu, Wenyan Li, Haiyan Huang, Runchang Li, Xinyu Ding, Yuerong Zhang, Xiaoyan Yu, Qiaoqiao Han, Xian Du, Jie Wan, Song Li, Yichuan Xiao, Ren Zhao, Xingang Cui, Youqiong Ye, Jiayuan Sun, Junke Zheng, Guo-Qiang Chen, Qiang Zou
{"title":"An age-related decrease in leptin contributes to CD8<sup>+</sup> T cell aging in the tumor microenvironment.","authors":"Feixiang Wang, Rujuan Bao, Shuiyu Xu, Wenyan Li, Haiyan Huang, Runchang Li, Xinyu Ding, Yuerong Zhang, Xiaoyan Yu, Qiaoqiao Han, Xian Du, Jie Wan, Song Li, Yichuan Xiao, Ren Zhao, Xingang Cui, Youqiong Ye, Jiayuan Sun, Junke Zheng, Guo-Qiang Chen, Qiang Zou","doi":"10.1016/j.xcrm.2025.102310","DOIUrl":null,"url":null,"abstract":"<p><p>T cell dysfunction with age underlies an increased incidence of cancer in elderly individuals; however, how T cell aging is triggered in the tumor microenvironment is unclear. Here, we show that an age-associated reduction in adipocyte-derived leptin contributes to the accumulation of tumor-infiltrating senescent CD8<sup>+</sup> T cells. Single-cell profiling of human and mouse cancer tissues reveals that the frequency of intratumoral senescent CD8<sup>+</sup> T cells increases with age, leading to a weak antitumor effect. Moreover, decreased levels of adipocyte-derived leptin are an indispensable factor for CD8<sup>+</sup> T cell aging. Leptin signaling prevents p38-dependent CD8<sup>+</sup> T cell senescence. Furthermore, plasma leptin levels are negatively related to intratumoral CD8<sup>+</sup> T cell senescence in cancer patients. Our findings identify an unappreciated interplay between metabolic perturbation and T cell aging and suggest that modulating adipocyte-derived leptin levels may be a promising therapeutic strategy for older cancer patients.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102310"},"PeriodicalIF":10.6000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490250/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Reports Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.xcrm.2025.102310","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
T cell dysfunction with age underlies an increased incidence of cancer in elderly individuals; however, how T cell aging is triggered in the tumor microenvironment is unclear. Here, we show that an age-associated reduction in adipocyte-derived leptin contributes to the accumulation of tumor-infiltrating senescent CD8+ T cells. Single-cell profiling of human and mouse cancer tissues reveals that the frequency of intratumoral senescent CD8+ T cells increases with age, leading to a weak antitumor effect. Moreover, decreased levels of adipocyte-derived leptin are an indispensable factor for CD8+ T cell aging. Leptin signaling prevents p38-dependent CD8+ T cell senescence. Furthermore, plasma leptin levels are negatively related to intratumoral CD8+ T cell senescence in cancer patients. Our findings identify an unappreciated interplay between metabolic perturbation and T cell aging and suggest that modulating adipocyte-derived leptin levels may be a promising therapeutic strategy for older cancer patients.
Cell Reports MedicineBiochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
CiteScore
15.00
自引率
1.40%
发文量
231
审稿时长
40 days
期刊介绍:
Cell Reports Medicine is an esteemed open-access journal by Cell Press that publishes groundbreaking research in translational and clinical biomedical sciences, influencing human health and medicine.
Our journal ensures wide visibility and accessibility, reaching scientists and clinicians across various medical disciplines. We publish original research that spans from intriguing human biology concepts to all aspects of clinical work. We encourage submissions that introduce innovative ideas, forging new paths in clinical research and practice. We also welcome studies that provide vital information, enhancing our understanding of current standards of care in diagnosis, treatment, and prognosis. This encompasses translational studies, clinical trials (including long-term follow-ups), genomics, biomarker discovery, and technological advancements that contribute to diagnostics, treatment, and healthcare. Additionally, studies based on vertebrate model organisms are within the scope of the journal, as long as they directly relate to human health and disease.